Modified Citrus Pectin Research

2023 Clinical Study: Final Long-term Results of MCP Treatment in Biochemically Relapsed Prostate Cancer

2021 Clinical Study: Modified Citrus Pectin Reduces PSA and Disease Progression in Biochemically Relapsed Prostate Cancer

2021 Preclinical Study: Modified Citrus Pectin blocks Galectin-3 and alleviates cardiac hypertrophy and cardiac dysfunction

2021 Preclinical Study: Modified Citrus Pectin inhibits breast cancer development in mice

2021 Translational Study: Galectin-3 as an early biomarker and potential therapeutic target for post-cardiac kidney injury—Modified Citrus Pectin attenuates damage

2021 Translational Study: Galectin-3 involved in sepsis-induced kidney injury—Modified Citrus Pectin reduces damage

2021 Preclinical Study: Modified Citrus Pectin inhibits fat accumulation in Non-Alcoholic Fatty Liver

2020 Preclinical Study: Modified Citrus Pectin inhibits Galectin-3 to Reduce Diabetes-Associated Cognitive Impairment, Oxidative Stress and Neuroinflammation

2020 Preclinical Study: Modified Citrus Pectin Targets Hypoxia-Induced Galectin-3 in Breast Cancer

2019 Clinical Study Updated Results: Modified Citrus Pectin Halts Biochemically-Relapsed Prostate Cancer

2019 Review: The Pleiotropic Effects of Modified Citrus Pectin

2019 Preclinical Study: Modified Citrus Pectin Targets Galectin-3-Induced STAT3 Activation to Synergize with Chemotherapy Drug Paclitaxel Against Ovarian Cancer

2019 Preclinical Study: Modified Citrus Pectin Improves Ischemic Heart Failure by Downregulating Galectin 3 and Reducing Myocardial Fibrosis

2019 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 to Prevent Profibrotic and Proinflammatory Effects of Cardiotrophin-1 (CT-1) in Myocardial Fibrosis

2019 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 and Prevents Cardiac Damage, Inflammation, and Fibrosis Following Kidney Injury

2019 Preclinical Study: Modified Citrus Pectin Blocked Galectin-3 and Reduced the Pro-Inflammatory, Pro-fibrotic, and Pro-osteogenic Response in Aortic valves in Patients Undergoing Aortic Valve Replacement

2019 Preclinical Study: Modified Citrus Pectin Blockade of Galectin-3 Prevents Cardiac Fibrosis, Inflammation and Functional Alterations

2019 Clinical Case Study: Modified Citrus Pectin and Alginate Combo Safely Remove Uranium

2018 Preclinical Study: Modified Citrus Pectin Prevents Blood-Brain Barrier Disruption in Mouse Subarachnoid Hemorrhage by Inhibiting Galectin-3

2018 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 and Protects Against Renal Injury and Fibrosis

2018 Clinical Study (Interim Results): Modified Citrus Pectin Halts Biochemically Relapsed Prostate Cancer

2018 Preclinical Study: Modified Citrus Pectin Inhibits Colon Cancer Migration via Galectin-3 Inhibition

2018 Practice Survey: Modified Citrus Pectin at Top of List for Naturopathic Treatment of Thoracic Cancer

2018 Preclinical Study: Modified Citrus Pectin Enhances Radiotherapy Against Prostate Cancer

2018 Preclinical Study: Modified Citrus Pectin Increases Antioxidant Activity and Reduces Oxidative Stress in Hypertension Model, through Inhibition of Galectin-3

2018 Preclinical Study: Modified Citrus Pectin Inhibits Bladder Tumor Growth through Downregulation of Galectin-3

2018 Preclinical Study: Inhibition of Galectin-3 with Modified Citrus Pectin Mitigates Diet-Induced Cardiac Lipotoxicity and Reduces Mitochondrial Damage

2018 Preclinical Study: Inhibition of Galectin-3 with Modified Citrus Pectin Reduces Inflammatory Mediators and Decreases Kidney Damage in Spontaneous Hypertension Model

2017 Preclinical Study: Modified Citrus Pectin Protects Vascular Tissue against Abdominal Aortic Aneurism by Decreasing Galectin-3 and Inflammatory Cytokine Expression

2017 Preclinical Study: Modified Citrus Pectin Combined with Alginate and Live Probiotic, Lactobacillus acidophilus Offered Benefit to Improve the Intestinal Lactobacilli Microbiota in Healthy Host

2017 Observational Study: Modified Citrus Pectin Listed Among Researched Nutrients with Anti-Carcinogenic Properties to Reduce CTC Count

2017 Preclinical Study: Modified Citrus Pectin Protects Against Shiga Toxin Adhesion and Cytotoxicity, via Prebiotic Actions

2017 Preclinical Study: Modified Citrus Pectin Reduces Size of Atherosclerotic Lesions, via Inhibition of Galectin-3

2017 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 to Prevent Cardiac Remodeling, Fibrosis and Inflammation Associated with Early Aortic Stenosis

2017 Preclinical Study: Modified Citrus Pectin and Pure Honokiol Offer Synergistic Antioxidant and Anti-inflammatory Effects, Reduce Tumor Necrosis-α (TNF-α), Nuclear factor-kappa B, Cyclooxygenase-II, and Lipid Peroxidation

2017 Preclinical Study: Modified Citrus Pectin Gives Additive Antibacterial Effect in Combination with Cefotaxime Against Staphylococcus aureusInfection

2017 Preclinical Study: Galectin-3 inhibition with Modified Citrus Pectin Blocks Inflammation, Fibrosis and Calcification in Aortic Valves

2016 Preclinical Study: Modified Citrus Pectin Reduces Renal Fibrosis, Inflammation and Damage, Through Inhibition of Galectin-3

2016 Preclinical Study: Modified Citrus Pectin Blocks Inflammation and Fibrosis and Prevents Calcification in Aortic Stenosis, via Inhibition of Galectin-3

2016 Preclinical Study: Modified Citrus Pectin Prevents Adipose (Fat)Tissue Remodeling in Obesity, via Inhibition of Galectin-3

2016 Preclinical Study: Modified Citrus Pectin Stops Progression of Liver Fibrosis Through Antioxidant Effect, Galectin-3 Inhibitionand Induction of Apoptosis

2016 Preclinical Study: Modified Citrus Pectin Inhibits Growth and Metastasis of Gastrointestinal Cancer Cells

2016 Preclinical Study: Modified Citrus Pectin Prevents Left Ventricle Dysfunction and Cardiac Fibrosis, through Inhibition of Galectin-3

2016 Preclinical Study: Modified Citrus pectin Suppresses Neuropathic Pain and Decreases Proinflammatory Mediators Following Peripheral Nerve Injury, via Inhibition of Galectin-3

2015 Preclinical Study: Modified Citrus Pectin Prevents Obesity-Related Cardiovascular Remodeling, through Inhibition of Galectin-3

2015 Preclinical Study: Modified Citrus Pectin Blocks Galectin-3 to Inhibit Cardiac Inflammation and Fibrosis in Experimental Hypertension

2015 Preclinical Study: Modified Citrus Pectin and Alginate Probiotic Combination offer Chemopreventive Effect against Colon Cancer Cells

2015 Preclinical Study: Modified Citrus Pectin Prevents Cardiac and Kidney Fibrosis, via Inhibition of Galectin-3

2013 Preclinical Study: Modified Citrus Pectin Reverses Vascular Hypertrophy and Fibrosis, via Inhibition of Galectin-3

2013 Preclinical Study: Modified Citrus Pectin Traverses Small Intestinal Epithelium Demonstrating increased Bioavailability

2013 Preclinical Study: Modified Citrus Pectin Demonstrates Synergistic Effect with Polybotanical Compounds for Breast and Prostate Cancer

2012 Preclinical Study: Synergistic Effects of Modified Citrus Pectin and Doxorubicin against Prostate Cancer Cells

2011 Preclinical Study: Modified Citrus Pectin Reduces Kidney Disease Severity by Reducing Galectin-3 Expression

2011 Preclinical Study: Modified Citrus Pectin Activates Powerful Immune Response

2011 Preclinical Study: Activation and Induction of Natural Killer Cell Activity Against Leukemia Cells with Modified Citrus Pectin

2010 Preclinical Study: Modified Citrus Pectin Inhibits Prostate Cancer

2010 Review: Modified Citrus Pectin Anti-Metastatic Properties

2009 Preclinical Study: Modified Citrus Pectin Binds to Galectin-3

2008 Clinical Study: The Role of Modified Citrus Pectin as an Effective Chelator of Lead in Children Hospitalized with Toxic Lead Levels

2007 Clinical Study: The Role of Modified Citrus Pectin/Alginates in Heavy Metal Chelation and Detoxification

2007 Clinical Study: Modified Citrus Pectin Clinical Benefit in Patients with Advanced Solid Tumors

2006 Clinical Study: The Effect of Modified Citrus Pectin on the Urinary Excretion of Toxic Elements

2003 Clinical Study: Modified Citrus Pectin (MCP) Increases the Prostate-Specific Antigen Doubling Time in Men with Prostate Cancer: A Phase II Pilot Study

To Read More, visit: PubMed

0
Your Cart
Your cart is empty
Payment plan details

Payment plan consists of 3 installments and includes a $300 upcharge per registrant. The 1st installment is due upon purchase, the 2nd installment will be charged automatically to the card on file 30 days from initial payment and the 3rd installment will be changed 60 days from initial payment.

Payment Plan is available through June 1st.

Please note that the payment plan option is only available for the retreat itself. Any add-ons will be due along with the initial retreat payment and registration.

Payment Plan Breakdown

SINGLE OCCUPANCY
Three installments of $1765 each

DOUBLE OCCUPANCY
Three installments of $2996 each ($1498 per registrant)

RATES & FEES
Extended Daily Rate for Add-On Dates to Retreat

* Daily rate is exclusive of taxes and resort experience fee.

Applicable to these dates only (supplies are limited)

Sunday, September 15th
Monday, September 16th
Saturday, September 21st
Sunday, September 22nd

Daily Rate: $499*

Total Rate: $645.23
Room G.E.T. Tax 4.71% / Room T.A.T. Tax 13.25%

Fees Details
The daily resort experience fee of $48 plus tax includes self-parking, internet access, wellness & cultural classes, shuttle bus service, lei greeting, 1 branded reusable water bottle per registered guest, snorkle rental (one hour/day), and local & domestic long distance calls.

Is your body's survival response working against you?

Download book excerpt

By submitting this form you are agreeing to receive email communications from Dr. Eliaz